Ocular Therapeutix Strengthens Its Workforce with Inducement Grants
Ocular Therapeutix, Inc. (NASDAQ: OCUL), a pioneering biopharmaceutical organization dedicated to transforming the retina experience, proudly announced an exciting development. Recently, the company granted inducement awards to eight newly recruited non-executive employees. This strategic move aligns with Ocular’s 2019 Inducement Stock Incentive Plan and adheres to Nasdaq Listing Rule 5635(c)(4).
Details of the Inducement Equity Awards
Effective December 1, 2025, the inducement grants comprise non-statutory stock options allowing the purchase of up to 51,600 shares of Ocular's common stock. Additionally, they include restricted stock unit awards entitling the recipients to an aggregate of 17,066 shares of the common stock. Notably, the stock options feature an exercise price of $11.71 per share, which corresponds to the closing price on The Nasdaq Global Market on the grant date.
Vesting Schedule and Terms
The stock options are set to a ten-year term and will vest over a four-year period. Specifically, 25% of the shares will vest on the one-year anniversary of each recipient's hiring date, while the remainder will vest in equal monthly increments over the next three years, ensuring recipients remain committed to Ocular throughout the vesting phases. Restricted stock unit awards will vest in equal annual installments over a three-year period, with the first installment set for December 1, 2026.
More About Ocular Therapeutix, Inc.
Ocular Therapeutix stands out as a transformative biopharmaceutical entity looking to redefine treatments for retinal disorders. One of its headline investigational products is AXPAXLI™ (also known as OTX-TKI), designed for treating retinal diseases, and is currently undergoing Phase 3 clinical trials targeting conditions such as wet age-related macular degeneration and non-proliferative diabetic retinopathy.
Pioneering Advances in Ocular Health
The company reinforces its commitment through its innovative pipeline, leveraging the proprietary ELUTYX™ technology. This is epitomized in its commercial product DEXTENZA®, an FDA-approved corticosteroid tailored for managing ocular inflammation and pain post-surgery in both adults and pediatric patients, as well as relieving allergic conjunctivitis symptoms in older children and adults. Concurrently, Ocular is investigating OTX-TIC, an intracamereal hydrogel that has successfully completed Phase 2 trials aimed at treating open-angle glaucoma or ocular hypertension.
Corporate Identity and Commitment to Innovation
Ocular Therapeutix isn’t just about innovation; it’s also about a solid corporate brand. The organization is focused on engaging with its community through various platforms, including their official website and social media channels. This dual approach not only showcases its commitment to its products but also emphasizes its desire to connect with stakeholders and the public.
Contacting Ocular Therapeutix
For those interested in learning more about Ocular Therapeutix or engaging with the company's investor relations, inquiries can be directed to Bill Slattery, Vice President of Investor Relations. Interested parties can reach him directly via email.
Frequently Asked Questions
What inducement awards did Ocular Therapeutix announce?
Ocular Therapeutix announced the granting of inducement equity awards to eight new employees, including stock options and restricted stock units.
What is the exercise price of the stock options?
The exercise price of the stock options is $11.71 per share, which matches the stock's closing price on the grant date.
How long is the vesting period for these awards?
The stock options vest over four years, with the initial 25% vesting one year after employment starts, followed by monthly vesting.
What pipeline products is Ocular Therapeutix currently focusing on?
Ocular is primarily focused on AXPAXLI™ for retinal diseases and DEXTENZA® for managing ocular inflammation and pain.
Who can be contacted for more information about Ocular Therapeutix?
For inquiries, contact Bill Slattery, Vice President of Investor Relations, via email.
